Clinical Success Alone Is No Longer Enough
The TCR‑Based Therapies field is entering a decisive new chapter.
While the first approved TCR‑T therapy validated the science, it did not solve the problem.
As the TCR landscape matures, developers are facing a significantly more complex environment. Across biotech and pharma, teams are contending with:
- Recent pipeline resets
- Asset sales and revised partnership models
- Rising development and manufacturing costs
- Narrow patient reach
Together, these forces are fundamentally changing how TCR programs are funded, partnered, and advanced.
This reflects the industry’s need for the 7th TCR-Based Therapies Summit, with the 2026 program built to address these issues, with sessions spanning:
Lowering Cost of Goods & Scalable Manufacturing
- How teams are reducing the cost of goods and building manufacturing models investors will back
- Designing scalability into TCR programs from early development
Expanding Patient Reach
- Moving beyond rare targets to broaden patient populations
- Approaches to targeting multiple HLA types and indications
What the Data Is Really Showing
- Insights from early clinical and late preclinical data on durability and persistence
- How response data is informing go / no‑go decisions
Overcoming the Tumor Microenvironment
- Next‑generation TCR engineering strategies for solid tumors
- Using novel targets and combination approaches to improve efficacy
Leave with Insights from Leaders Making the Hard Calls
A defining feature of this year’s summit is its’ 55% C-suite level speaker faculty, making this is the only place where you can gain direct insight from, and engage with, executives and senior scientific leaders actively shaping the next generation of TCR‑based cell and biologic therapies.
You’ll hear firsthand from innovators including:
...and many more!
Join the Conversations Shaping What Comes Next
Unlike broader cell therapy or biologics meetings, the TCR-Based Therapies Summit provides a focused forum to benchmark how peers are navigating the most critical technical and strategic choices across the TCR lifecycle, including:
- TCR Discovery & Development Strategy
- Target Selection & HLA Matching
- Managing Cross‑Reactivity & Safety Risk
- Next‑Generation TCR Engineering
Join us in Boston to benchmark decisions and pressure test strategies with peers facing the same technical and commercial constraints.
Can your team really afford to fall behind?